Which has preferable valuation and earnings, BRKR or TECH?

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.50B 2.51 -$8.60M -$0.70 N/A Bio-Techne $1.22B 9.33 $181.86M $1.15 62.96

Is BRKR or TECH more profitable?

Bio-Techne has a net margin of 14.97% compared to Bruker's net margin of -2.35%. Bio-Techne's return on equity of 13.23% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -2.35% 12.47% 4.91% Bio-Techne 14.97% 13.23% 10.61%

Does the media favor BRKR or TECH?

In the previous week, Bio-Techne had 14 more articles in the media than Bruker. MarketBeat recorded 22 mentions for Bio-Techne and 8 mentions for Bruker. Bio-Techne's average media sentiment score of 0.88 beat Bruker's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or BRKR?

In the previous week, Agilent Technologies had 21 more articles in the media than Bruker. MarketBeat recorded 29 mentions for Agilent Technologies and 8 mentions for Bruker. Agilent Technologies' average media sentiment score of 1.56 beat Bruker's score of 0.80 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 26 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bruker 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IQV or BRKR?

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.38 $1.36B $8.06 29.30 Bruker $3.50B 2.51 -$8.60M -$0.70 N/A

Is IQV or BRKR more profitable?

IQVIA has a net margin of 8.10% compared to Bruker's net margin of -2.35%. IQVIA's return on equity of 30.25% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Bruker -2.35% 12.47% 4.91%

Does the media prefer IQV or BRKR?

In the previous week, Bruker had 4 more articles in the media than IQVIA. MarketBeat recorded 8 mentions for Bruker and 4 mentions for IQVIA. IQVIA's average media sentiment score of 0.84 beat Bruker's score of 0.80 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BRKR or MTD?

In the previous week, Bruker had 2 more articles in the media than Mettler-Toledo International. MarketBeat recorded 8 mentions for Bruker and 6 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.41 beat Bruker's score of 0.80 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, RVTY or BRKR?

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 4.56 $241.20M $2.10 55.58 Bruker $3.50B 2.51 -$8.60M -$0.70 N/A

Is RVTY or BRKR more profitable?

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.16% 8.34% 5.01% Bruker -2.35% 12.47% 4.91%

Does the media refer more to RVTY or BRKR?

In the previous week, Bruker had 2 more articles in the media than Revvity. MarketBeat recorded 8 mentions for Bruker and 6 mentions for Revvity. Bruker's average media sentiment score of 0.80 beat Revvity's score of 0.56 indicating that Bruker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bruker 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bruker (BRKR) Competitors

$57.70 -0.23 (-0.40%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$57.72 +0.02 (+0.03%)

As of 08/14/2026 07:40 PM Eastern

Compare

BRKR vs. TECH, A, IQV, MTD, and RVTY

Should you buy Bruker stock or one of its competitors? Bruker's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), Mettler-Toledo International (MTD), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bruker compare to Bio-Techne?

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Bio-Techne had 14 more articles in the media than Bruker. MarketBeat recorded 22 mentions for Bio-Techne and 8 mentions for Bruker. Bio-Techne's average media sentiment score of 0.88 beat Bruker's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Bruker shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 27.2% of Bruker shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.50B	2.51	-$8.60M	-$0.70	N/A
Bio-Techne	$1.22B	9.33	$181.86M	$1.15	62.96

Bruker has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Bruker presently has a consensus price target of $56.64, indicating a potential downside of 1.83%. Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 4.80%. Given Bruker's stronger consensus rating and higher probable upside, analysts plainly believe Bruker is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Bio-Techne has a net margin of 14.97% compared to Bruker's net margin of -2.35%. Bio-Techne's return on equity of 13.23% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Bio-Techne	14.97%	13.23%	10.61%

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Bruker pays out -28.6% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bio-Techne beats Bruker on 11 of the 18 factors compared between the two stocks.

How does Bruker compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

79.5% of Bruker shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Agilent Technologies has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.04	$1.30B	$4.98	29.83
Bruker	$3.50B	2.51	-$8.60M	-$0.70	N/A

Agilent Technologies has a net margin of 19.55% compared to Bruker's net margin of -2.35%. Agilent Technologies' return on equity of 24.33% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Bruker	-2.35%	12.47%	4.91%

In the previous week, Agilent Technologies had 21 more articles in the media than Bruker. MarketBeat recorded 29 mentions for Agilent Technologies and 8 mentions for Bruker. Agilent Technologies' average media sentiment score of 1.56 beat Bruker's score of 0.80 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	26 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bruker	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies presently has a consensus price target of $160.24, indicating a potential upside of 7.87%. Bruker has a consensus price target of $56.64, indicating a potential downside of 1.83%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57

Agilent Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Bruker has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.7%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Bruker pays out -28.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Agilent Technologies beats Bruker on 15 of the 19 factors compared between the two stocks.

How does Bruker compare to IQVIA?

IQVIA (NYSE:IQV) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.38	$1.36B	$8.06	29.30
Bruker	$3.50B	2.51	-$8.60M	-$0.70	N/A

IQVIA has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Bruker has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

IQVIA has a net margin of 8.10% compared to Bruker's net margin of -2.35%. IQVIA's return on equity of 30.25% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Bruker	-2.35%	12.47%	4.91%

IQVIA presently has a consensus target price of $241.88, indicating a potential upside of 2.42%. Bruker has a consensus target price of $56.64, indicating a potential downside of 1.83%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts clearly believe IQVIA is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57

In the previous week, Bruker had 4 more articles in the media than IQVIA. MarketBeat recorded 8 mentions for Bruker and 4 mentions for IQVIA. IQVIA's average media sentiment score of 0.84 beat Bruker's score of 0.80 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bruker	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 27.2% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IQVIA beats Bruker on 12 of the 17 factors compared between the two stocks.

How does Bruker compare to Mettler-Toledo International?

Bruker (NASDAQ:BRKR) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Bruker had 2 more articles in the media than Mettler-Toledo International. MarketBeat recorded 8 mentions for Bruker and 6 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.41 beat Bruker's score of 0.80 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Bruker shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bruker has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Bruker presently has a consensus price target of $56.64, suggesting a potential downside of 1.83%. Mettler-Toledo International has a consensus price target of $1,461.27, suggesting a potential upside of 3.10%. Given Mettler-Toledo International's higher probable upside, analysts plainly believe Mettler-Toledo International is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.50B	2.51	-$8.60M	-$0.70	N/A
Mettler-Toledo International	$4.03B	7.05	$869.19M	$44.43	31.90

Mettler-Toledo International has a net margin of 21.91% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Summary

Mettler-Toledo International beats Bruker on 10 of the 16 factors compared between the two stocks.

How does Bruker compare to Revvity?

Revvity (NYSE:RVTY) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays out 13.3% of its earnings in the form of a dividend. Bruker pays out -28.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 27.2% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Bruker	-2.35%	12.47%	4.91%

In the previous week, Bruker had 2 more articles in the media than Revvity. MarketBeat recorded 8 mentions for Bruker and 6 mentions for Revvity. Bruker's average media sentiment score of 0.80 beat Revvity's score of 0.56 indicating that Bruker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bruker	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.56	$241.20M	$2.10	55.58
Bruker	$3.50B	2.51	-$8.60M	-$0.70	N/A

Revvity presently has a consensus price target of $108.36, suggesting a potential downside of 7.15%. Bruker has a consensus price target of $56.64, suggesting a potential downside of 1.83%. Given Bruker's stronger consensus rating and higher probable upside, analysts plainly believe Bruker is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57

Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Bruker has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Bruker beats Revvity on 12 of the 19 factors compared between the two stocks.

Get Bruker News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRKR vs. The Competition

Export

Metric	Bruker	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.79B	$9.57B	$7.04B	$13.06B
Dividend Yield	0.35%	1.46%	2.56%	10.63%
P/E Ratio	-82.43	60.31	271.26	25.30
Price / Sales	2.51	105.70	603.81	99.64
Price / Cash	17.09	26.11	28.87	38.43
Price / Book	3.54	5.06	11.17	6.52
Net Income	-$8.60M	$56.67B	$3.45B	$346.94M
7 Day Performance	8.03%	0.29%	1.17%	1.08%
1 Month Performance	-2.62%	2.08%	2.18%	1.87%
1 Year Performance	72.14%	17.23%	62.39%	20.79%

Bruker Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRKR Bruker	2.8178 of 5 stars	$57.70 -0.4%	$56.64 -1.8%	+72.1%	$8.79B	$3.50B	N/A	11,085
TECH Bio-Techne	3.1458 of 5 stars	$72.14 +0.1%	$68.08 -5.6%	+35.1%	$11.29B	$1.22B	104.55	3,100	News Coverage Earnings Report Dividend Announcement Analyst Downgrade
A Agilent Technologies	4.8147 of 5 stars	$139.88 +1.1%	$159.35 +13.9%	+24.5%	$39.08B	$6.95B	28.09	18,100	News Coverage Positive News Analyst Forecast
IQV IQVIA	4.0318 of 5 stars	$233.37 -0.7%	$241.88 +3.6%	+23.5%	$38.68B	$16.31B	28.95	93,000
MTD Mettler-Toledo International	3.1314 of 5 stars	$1,446.84 +2.2%	$1,445.36 -0.1%	+7.7%	$28.62B	$4.03B	32.56	18,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRKR) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bruker (BRKR) Competitors